CoChat

Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets

Open access
Mottini, Carla, Napolitano, Francesco, Li, Zhongxiao, Gao, Xin, Cardone, Luca · 2021 · Seminars in Cancer Biology
Cited by 118

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

Despite huge efforts made in academic and pharmaceutical worldwide research, current anticancer therapies achieve effective treatment in a limited number of neoplasia cases only. Oncology terms such as big killers - to identify tumours with yet a high mortality rate - or undruggable cancer targets, and chemoresistance, represent the current therapeutic debacle of cancer treatments. In addition, metastases, tumour microenvironments, tumour heterogeneity, metabolic adaptations, and immunotherapy resistance are essential features controlling tumour response to therapies, but still, lack effective therapeutics or modulators. In this scenario, where the pharmaceutical productivity and drug efficacy in oncology seem to have reached a plateau, the so-called drug repurposing - i.e. the use of old drugs, already in clinical use, for a different therapeutic indication - is an appealing strategy to improve cancer therapy. Opportunities for drug repurposing are often based on occasional observations or on time-consuming pre-clinical drug screenings that are often not hypothesis-driven. In contrast, in-silico drug repurposing is an emerging, hypothesis-driven approach that takes advantage of the use of big-data. Indeed, the extensive use of -omics technologies, improved data storage, data meaning, machine learning algorithms, and computational modeling all offer unprecedented knowledge of the biological mechanisms of cancers and drugs' modes of action, providing extensive availability for both disease-related data and drugs-related data. This offers the opportunity to generate, with time and cost-effective approaches, computational drug networks to predict, in-silico, the efficacy of approved drugs against relevant cancer targets, as well as to select better responder patients or disease' biomarkers. Here, we will review selected disease-related data together with computational tools to be exploited for the in-silico repurposing of drugs against validated targets in cancer therapies, focusing on the oncogenic signaling pathways activation in cancer. We will discuss how in-silico drug repurposing has the promise to shortly improve our arsenal of anticancer drugs and, likely, overcome certain limitations of modern cancer therapies against old and new therapeutic targets in oncology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.semcancer.2019.09.023

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 156

  1. Booth, 2004, Prospects for productivity, Nat. Rev. Drug Discov., 3, 451, 10.1038/nrd1384 · DOI · Paper page
  2. Shih, 2018, Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications, Nat. Rev. Drug Discov., 17, 19, 10.1038/nrd.2017.194 · DOI
  3. Patel, 2017, Phase 2 to phase 3 clinical trial transitions: reasons for success and failure in immunologic diseases, J. Allergy Clin. Immunol., 140, 685, 10.1016/j.jaci.2017.04.029 · DOI
  4. Mohs, 2017, Drug discovery and development: role of basic biological research, Alzheimers Dement. N. Y., 3, 651, 10.1016/j.trci.2017.10.005 · DOI · Paper page
  5. Glode, 2017, Rising cost of Cancer pharmaceuticals: cost issues and interventions to control costs, Pharmacotherapy, 37, 85, 10.1002/phar.1867 · DOI
  6. Malik, 2009, Controlling the cost of innovative cancer therapeutics, Nat. Rev. Clin. Oncol., 6, 550, 10.1038/nrclinonc.2009.113 · DOI
  7. Papapetropoulos, 2018, Inventing new therapies without reinventing the wheel: the power of drug repurposing, Br. J. Pharmacol., 175, 165, 10.1111/bph.14081 · DOI
  8. Shaughnessy, 2011, Old drugs, new tricks, BMJ, 342, d741, 10.1136/bmj.d741 · DOI
  9. Kimmelman, 2018, The paradox of precision medicine, Nat. Rev. Clin. Oncol., 15, 341, 10.1038/s41571-018-0016-0 · DOI
  10. Cha, 2018, Drug repurposing from the perspective of pharmaceutical companies, Br. J. Pharmacol., 175, 168, 10.1111/bph.13798 · DOI · Paper page
  11. Wilkinson, 2015, In vitro screening for drug repositioning, J. Biomol. Screen., 20, 167, 10.1177/1087057114563024 · DOI
  12. Iljin, 2009, High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth, Clin. Cancer Res., 15, 6070, 10.1158/1078-0432.CCR-09-1035 · DOI · Paper page
  13. Chateauvieux, 2010, Molecular and therapeutic potential and toxicity of valproic acid, J. Biomed. Biotechnol., 2010, 10.1155/2010/479364 · DOI · Paper page
  14. Shim, 2014, Recent advances in drug repositioning for the discovery of new anticancer drugs, Int. J. Biol. Sci., 10, 654, 10.7150/ijbs.9224 · DOI · Paper page
  15. Calvo, 2016, Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics in the Era of Targeted Therapies, Am. Soc. Clin. Oncol. Educ. Book, 35, e175, 10.1200/EDBK_159061 · DOI
  16. Gillies, 2018, Eco-evolutionary causes and consequences of temporal changes in intratumoural blood flow, Nat. Rev. Cancer, 18, 576, 10.1038/s41568-018-0030-7 · DOI · Paper page
  17. Menden, 2019, Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen, Nat. Commun., 10, 2674, 10.1038/s41467-019-09799-2 · DOI · Paper page
  18. Huang, 2014, Systematic prediction of drug combinations based on clinical side-effects, Sci. Rep., 4, 7160, 10.1038/srep07160 · DOI · Paper page
  19. Pemovska, 2013, Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia, Cancer Discov., 3, 1416, 10.1158/2159-8290.CD-13-0350 · doi:10.1158/2159-8290.cd-13-0350
  20. Shaked, 2016, Metabolic network prediction of drug side effects, Cell Syst., 2, 209, 10.1016/j.cels.2016.03.001 · DOI
  21. von Eichborn, 2011, PROMISCUOUS: a database for network-based drug-repositioning, Nucleic Acids Res., 39, D1060, 10.1093/nar/gkq1037 · DOI · Paper page
  22. Yang, 2011, Systematic drug repositioning based on clinical side-effects, PLoS One, 6, 10.1371/journal.pone.0028025 · DOI · Paper page
  23. Ye, 2014, Construction of drug network based on side effects and its application for drug repositioning, PLoS One, 9, 10.1371/journal.pone.0087864 · DOI
  24. Camacho, 2018, Next-generation machine learning for biological networks, Cell, 173, 1581, 10.1016/j.cell.2018.05.015 · DOI · Paper page
  25. Gottlieb, 2011, PREDICT: a method for inferring novel drug indications with application to personalized medicine, Mol. Syst. Biol., 7, 496, 10.1038/msb.2011.26 · DOI · Paper page
  26. Mottini, 2019, Predictive signatures inform the effective repurposing of Decitabine to treat K-RAS-dependent Pancreatic Ductal Adenocarcinoma, Cancer Res., 10.1158/0008-5472.CAN-19-0187 · DOI
  27. Karczewski, 2012, Chapter 7: pharmacogenomics, PLoS Comput. Biol., 8, 10.1371/journal.pcbi.1002817 · DOI · Paper page
  28. Oprea, 2015, Computational and practical aspects of drug repositioning, Assay Drug Dev. Technol., 13, 299, 10.1089/adt.2015.29011.tiodrrr · DOI · Paper page
  29. Wu, 2016, SDTNBI: an integrated network and chemoinformatics tool for systematic prediction of drug–target interactions and drug repositioning, Brief. Bioinformatics, 18, 333
  30. Gaulton, 2017, The ChEMBL database in 2017, Nucleic Acids Res., 45, D945, 10.1093/nar/gkw1074 · DOI · Paper page
  31. Yap, 2011, PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints, J. Comput. Chem., 32, 1466, 10.1002/jcc.21707 · DOI · Paper page
  32. Gong, 2013, ChemMapper: a versatile web server for exploring pharmacology and chemical structure association based on molecular 3D similarity method, Bioinformatics, 29, 1827, 10.1093/bioinformatics/btt270 · DOI · Paper page
  33. Wang, 2015, Inhibition of human copper trafficking by a small molecule significantly attenuates cancer cell proliferation, Nat. Chem., 7, 968, 10.1038/nchem.2381 · DOI · Paper page
  34. Liang, 2017, LRSSL: predict and interpret drug–disease associations based on data integration using sparse subspace learning, Bioinformatics, 33, 1187, 10.1093/bioinformatics/btw770 · DOI · Paper page
  35. Vidović, 2014, Large-scale integration of small molecule-induced genome-wide transcriptional responses, Kinome-wide binding affinities and cell-growth inhibition profiles reveal global trends characterizing systems-level drug action, Front. Genet., 5, 342
  36. Cheng, 2016, Systematic quality control analysis of LINCS data, CPT Pharmacometrics Syst. Pharmacol., 5, 588, 10.1002/psp4.12107 · DOI
  37. Huang, 2018, Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma, Sci. Transl. Med., 10, 10.1126/scitranslmed.aat0150 · DOI
  38. Chen, 2016, A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer, BMC Med. Genomics, 9, 51, 10.1186/s12920-016-0212-7 · DOI
  39. Iorio, 2010, Discovery of drug mode of action and drug repositioning from transcriptional responses, Proc. Natl. Acad. Sci., 107, 14621, 10.1073/pnas.1000138107 · DOI · Paper page
  40. Carrella, 2014, Mantra 2.0: an online collaborative resource for drug mode of action and repurposing by network analysis, Bioinformatics, 30, 1787, 10.1093/bioinformatics/btu058 · DOI
  41. Carrella, 2016, Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds, Oncotarget, 7, 58743, 10.18632/oncotarget.11318 · DOI · Paper page
  42. Napolitano, 2016, Drug-set enrichment analysis: a novel tool to investigate drug mode of action, Bioinformatics, 32, 235, 10.1093/bioinformatics/btv536 · DOI · Paper page
  43. Napolitano, 2017, gene2drug: a computational tool for pathway-based rational drug repositioning, Bioinformatics, 34, 1498, 10.1093/bioinformatics/btx800 · DOI · Paper page
  44. Whirl-Carrillo, 2012, Pharmacogenomics knowledge for personalized medicine, Clin. Pharmacol. Ther., 92, 414, 10.1038/clpt.2012.96 · DOI · Paper page
  45. Igarashi, 2015, Open TG-GATEs: a large-scale toxicogenomics database, Nucleic Acids Res., 43, D921, 10.1093/nar/gku955 · DOI · Paper page
  46. Sirota, 2011, Discovery and preclinical validation of drug indications using compendia of public gene expression data, Sci. Transl. Med., 3, 10.1126/scitranslmed.3001318 · DOI · Paper page
  47. Dudley, 2011, Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease, Sci. Transl. Med., 3, 10.1126/scitranslmed.3002648 · DOI · Paper page
  48. Kim, 2019, Computational drug repositioning for gastric Cancer using reversal gene expression profiles, Sci. Rep., 9, 2660, 10.1038/s41598-019-39228-9 · DOI
  49. Yang, 2014, Drug-disease association and drug-repositioning predictions in complex diseases using causal inference-probabilistic matrix factorization, J. Chem. Inf. Model., 54, 2562, 10.1021/ci500340n · DOI
  50. Li, 2013, Pathway-based drug repositioning using causal inference, BMC Bioinformatics, 14, S3, 10.1186/1471-2105-14-S16-S3 · DOI
  51. Zhang, 2014, Towards drug repositioning: a unified computational framework for integrating multiple aspects of drug similarity and disease similarity, AMIA Annu. Symp. Proc., 2014, 1258
  52. Chen, 2012, Predicting anatomical therapeutic chemical (ATC) classification of drugs by integrating chemical-Chemical interactions and similarities, PLoS One, 7
  53. Wang, 2013, Network predicting drug’s anatomical therapeutic chemical code, Bioinformatics, 29, 1317, 10.1093/bioinformatics/btt158 · DOI
  54. Pagliarini, 2016, In silico modeling of liver metabolism in a human disease reveals a key enzyme for histidine and histamine homeostasis, Cell Rep., 15, 2292, 10.1016/j.celrep.2016.05.014 · DOI
  55. Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9 · DOI · Paper page
  56. Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
  57. N. Cancer Genome Atlas, 2012, Comprehensive molecular portraits of human breast tumours, Nature, 490, 61, 10.1038/nature11412 · DOI · Paper page
  58. N. Cancer Genome Atlas Research, 2008, Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature, 455, 1061, 10.1038/nature07385 · DOI · Paper page
  59. N. Cancer Genome Atlas Research, 2011, Integrated genomic analyses of ovarian carcinoma, Nature, 474, 609, 10.1038/nature10166 · DOI · Paper page
  60. N. Cancer Genome Atlas Research, 2014, Comprehensive molecular characterization of urothelial bladder carcinoma, Nature, 507, 315, 10.1038/nature12965 · DOI
  61. N. Cancer Genome Atlas Research, 2017, Integrated genomic and molecular characterization of cervical cancer, Nature, 543, 378, 10.1038/nature21386 · DOI · Paper page
  62. Hoadley, 2014, Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin, Cell, 158, 929, 10.1016/j.cell.2014.06.049 · DOI · Paper page
  63. Liu, 2018, N. Cancer genome atlas research, H. Hu, an integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics, Cell, 173, 400, 10.1016/j.cell.2018.02.052 · DOI · Paper page
  64. Mejia-Pedroza, 2018, Pathway-based drug repositioning for breast Cancer Molecular subtypes, Front. Pharmacol., 9, 905, 10.3389/fphar.2018.00905 · DOI
  65. Lee, 2016, Drug repositioning for Cancer therapy based on large-scale drug-induced transcriptional signatures, PLoS One, 11, 10.1371/journal.pone.0150460 · DOI · Paper page
  66. Xu, 2018, Accurate drug repositioning through non-tissue-Specific core signatures from Cancer transcriptomes, Cell Rep., 25, 523, 10.1016/j.celrep.2018.09.031 · DOI
  67. Turanli, 2019, Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning, EBioMedicine, 42, 386, 10.1016/j.ebiom.2019.03.009 · DOI
  68. Yang, 2019, Novel drug candidate for the treatment of several softtissue sarcoma histologic subtypes: a computational method using survivalassociated gene signatures for drug repurposing, Oncol. Rep., 41, 2241
  69. Luo, 2009, Principles of cancer therapy: oncogene and non-oncogene addiction, Cell, 136, 823, 10.1016/j.cell.2009.02.024 · DOI · Paper page
  70. Pagliarini, 2015, Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure, EMBO Rep., 16, 280, 10.15252/embr.201439949 · DOI · Paper page
  71. Nussinov, 2016, A new view of ras isoforms in cancers, Cancer Res., 76, 18, 10.1158/0008-5472.CAN-15-1536 · DOI · Paper page
  72. Qian, 2005, In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis, Cancer Res., 65, 5045, 10.1158/0008-5472.CAN-04-3208 · DOI · Paper page
  73. Tsang, 2016, Functional annotation of rare gene aberration drivers of pancreatic cancer, Nat. Commun., 7, 10500, 10.1038/ncomms10500 · DOI · Paper page
  74. Vallejo, 2017, An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer, Nat. Commun., 8, 14294, 10.1038/ncomms14294 · DOI · Paper page
  75. Stelniec-Klotz, 2012, Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS, Mol. Syst. Biol., 8, 601, 10.1038/msb.2012.32 · DOI
  76. Singh, 2009, A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival, Cancer Cell, 15, 489, 10.1016/j.ccr.2009.03.022 · DOI · Paper page
  77. Brijwani, 2017, Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2, Sci. Rep., 7, 1502, 10.1038/s41598-017-01566-x · DOI
  78. Ntai, 2018, Precise characterization of KRAS4b proteoforms in human colorectal cells and tumors reveals mutation/modification cross-talk, Proc. Natl. Acad. Sci. U. S. A., 115, 4140, 10.1073/pnas.1716122115 · DOI · Paper page
  79. Demory Beckler, 2013, Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS, Mol. Cell Proteomics, 12, 343, 10.1074/mcp.M112.022806 · DOI · Paper page
  80. Ye, 2016, Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface, Oncotarget, 7, 86948, 10.18632/oncotarget.13566 · DOI
  81. Brunelli, 2016, Comparative metabolomics profiling of isogenic KRAS wild type and mutant NSCLC cells in vitro and in vivo, Sci. Rep., 6, 28398, 10.1038/srep28398 · DOI
  82. Charitou, 2019, Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRAS(G13D) mutation, Br. J. Cancer, 121, 37, 10.1038/s41416-019-0477-7 · DOI
  83. LaConti, 2015, Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma, BMC Genomics, 16, S1, 10.1186/1471-2164-16-S1-S1 · DOI
  84. Chen, 2018, Targeting oncogenic Myc as a strategy for cancer treatment, Signal Transduct. Target. Ther., 3, 5, 10.1038/s41392-018-0008-7 · DOI · Paper page
  85. Kalkat, 2017, MYC deregulation in primary human cancers, Genes (Basel), 8, 10.3390/genes8060151 · DOI · Paper page
  86. Whitfield, 2017, Strategies to inhibit myc and their clinical applicability, Front. Cell Dev. Biol., 5, 10, 10.3389/fcell.2017.00010 · DOI · Paper page
  87. Lopez, 2019, Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma, Nat. Commun., 10, 1459, 10.1038/s41467-019-08578-3 · DOI
  88. Horiuchi, 2012, MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition, J. Exp. Med., 209, 679, 10.1084/jem.20111512 · DOI · Paper page
  89. Wolfer, 2010, MYC regulation of a "poor-prognosis" metastatic cancer cell state, Proc Natl Acad Sci U S A, 107, 3698, 10.1073/pnas.0914203107 · DOI · Paper page
  90. Yang, 2017, A c-Myc-regulated stem cell-like signature in high-risk neuroblastoma: a systematic discovery (Target neuroblastoma ESC-like signature), Sci. Rep., 7, 41, 10.1038/s41598-017-00122-x · DOI
  91. Shachaf, 2008, Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance, Cancer Res., 68, 5132, 10.1158/0008-5472.CAN-07-6192 · DOI · Paper page
  92. Kalkat, 2018, MYC protein interactome profiling reveals functionally distinct regions that cooperate to drive tumorigenesis, Mol. Cell, 72, 836, 10.1016/j.molcel.2018.09.031 · DOI · Paper page
  93. Pan, 2009, Quantitative proteomics investigation of pancreatic intraepithelial neoplasia, Electrophoresis, 30, 1132, 10.1002/elps.200800752 · DOI
  94. Shiio, 2002, Quantitative proteomic analysis of Myc oncoprotein function, EMBO J., 21, 5088, 10.1093/emboj/cdf525 · DOI · Paper page
  95. Elkon, 2015, Myc coordinates transcription and translation to enhance transformation and suppress invasiveness, EMBO Rep., 16, 1723, 10.15252/embr.201540717 · DOI
  96. Tu, 2018, MYC interacts with the G9a histone methyltransferase to drive transcriptional repression and tumorigenesis, Cancer Cell, 34, 579, 10.1016/j.ccell.2018.09.001 · DOI
  97. Tarrado-Castellarnau, 2017, De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition, Mol. Syst. Biol., 13, 940, 10.15252/msb.20167321 · DOI
  98. Hall, 2016, Myc expression drives aberrant lipid metabolism in lung Cancer, Cancer Res., 76, 4608, 10.1158/0008-5472.CAN-15-3403 · DOI
  99. Satoh, 2017, Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC, Proc. Natl. Acad. Sci. U. S. A., 114, E7697, 10.1073/pnas.1710366114 · DOI · Paper page
  100. Camarda, 2016, Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer, Nat. Med., 22, 427, 10.1038/nm.4055 · DOI · Paper page
  101. Bott, 2015, Oncogenic myc induces expression of glutamine synthetase through promoter demethylation, Cell Metab., 22, 1068, 10.1016/j.cmet.2015.09.025 · DOI · Paper page
  102. Daugherty, 2007, Phospho-regulation of Beta-catenin adhesion and signaling functions, Physiology Bethesda, 22, 303, 10.1152/physiol.00020.2007 · DOI · Paper page
  103. Kahn, 2014, Can we safely target the WNT pathway?, Nat. Rev. Drug Discov., 13, 513, 10.1038/nrd4233 · DOI · Paper page
  104. Polakis, 2012, Drugging Wnt signalling in cancer, EMBO J., 31, 2737, 10.1038/emboj.2012.126 · DOI · Paper page
  105. Chen, 2010, Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry, J. Proteome Res., 9, 4215, 10.1021/pr1005197 · DOI
  106. Ewing, 2018, Multiproteomic and transcriptomic analysis of oncogenic beta-catenin molecular networks, J. Proteome Res., 17, 2216, 10.1021/acs.jproteome.8b00180 · DOI
  107. Vergara, 2017, Beta-catenin knockdown affects mitochondrial biogenesis and lipid metabolism in breast Cancer cells, Front. Physiol., 8, 544, 10.3389/fphys.2017.00544 · DOI · Paper page
  108. Voloshanenko, 2018, Beta-catenin-independent regulation of Wnt target genes by RoR2 and ATF2/ATF4 in colon cancer cells, Sci. Rep., 8, 3178, 10.1038/s41598-018-20641-5 · DOI
  109. Semaan, 2019, Proteomic screen with the proto-oncogene beta-catenin identifies interaction with Golgi coatomer complex I, Biochem. Biophys. Rep., 19
  110. Rosenbluh, 2016, Genetic and proteomic interrogation of lower confidence candidate genes reveals signaling networks in beta-catenin-Active cancers, Cell Syst., 3, 302, 10.1016/j.cels.2016.09.001 · DOI · Paper page
  111. Chang, 2015, Diverse targets of beta-catenin during the epithelial-mesenchymal transition define Cancer stem cells and predict disease relapse, Cancer Res., 75, 3398, 10.1158/0008-5472.CAN-14-3265 · DOI
  112. Nsengimana, 2018, Beta-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas, J. Clin. Invest., 128, 2048, 10.1172/JCI95351 · DOI · Paper page
  113. Wang, 2018, Targeting Wnt/beta-Catenin signaling for Cancer immunotherapy, Trends Pharmacol. Sci., 39, 648, 10.1016/j.tips.2018.03.008 · DOI · Paper page
  114. Bou-Hanna, 2015, Acute cytotoxicity of MIRA-1/NSC19630, a mutant p53-reactivating small molecule, against human normal and cancer cells via a caspase-9-dependent apoptosis, Cancer Lett., 359, 211, 10.1016/j.canlet.2015.01.014 · DOI
  115. Duffy, 2017, Mutant p53 as a target for cancer treatment, Eur. J. Cancer, 83, 258, 10.1016/j.ejca.2017.06.023 · DOI · Paper page
  116. Liang, 2009, PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein, Int. J. Oncol., 35, 1015
  117. Zandi, 2011, PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53, Clin. Cancer Res., 17, 2830, 10.1158/1078-0432.CCR-10-3168 · DOI · Paper page
  118. Zhao, 2017, Molecularly targeted therapies for p53-mutant cancers, Cell. Mol. Life Sci., 74, 4171, 10.1007/s00018-017-2575-0 · DOI
  119. Pfefferle, 2016, Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers, Dis. Model. Mech., 9, 749
  120. Tanikawa, 2017, The transcriptional landscape of p53 signalling pathway, EBioMedicine, 20, 109, 10.1016/j.ebiom.2017.05.017 · DOI
  121. Arandkar, 2018, Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features, Proc Natl Acad Sci U S A, 115, 6410, 10.1073/pnas.1719076115 · DOI · Paper page
  122. Badal, 2017, Transcriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulation, JCI Insight, 2, 10.1172/jci.insight.92102 · DOI
  123. Sanchez, 2014, Genome-wide analysis of the human p53 transcriptional network unveils a lncRNA tumour suppressor signature, Nat. Commun., 5, 5812, 10.1038/ncomms6812 · DOI · Paper page
  124. Koifman, 2018, A mutant p53-Dependent embryonic stem cell gene signature is associated with augmented tumorigenesis of stem cells, Cancer Res., 78, 5833, 10.1158/0008-5472.CAN-18-0805 · DOI
  125. Taguchi, 2014, Proteomic signatures associated with p53 mutational status in lung adenocarcinoma, Proteomics, 14, 2750, 10.1002/pmic.201400378 · DOI
  126. Hunten, 2015, p53-Regulated Networks of Protein, mRNA, miRNA, and lncRNA Expression Revealed by Integrated Pulsed Stable Isotope Labeling With Amino Acids in Cell Culture (pSILAC) and Next Generation Sequencing (NGS) Analyses, Mol. Cell Proteomics, 14, 2609, 10.1074/mcp.M115.050237 · DOI · Paper page
  127. Novo, 2018, Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels, Nat. Commun., 9, 5069, 10.1038/s41467-018-07339-y · DOI · Paper page
  128. Andrysik, 2017, Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activity, Genome Res., 27, 1645, 10.1101/gr.220533.117 · DOI · Paper page
  129. Lowman, 2019, M.B. Ishak Gabra, T.Q. tran, H. Li, M. Kong, p53 promotes Cancer cell adaptation to glutamine deprivation by upregulating Slc7a3 to increase arginine uptake, Cell Rep., 26, 3051, 10.1016/j.celrep.2019.02.037 · DOI · Paper page
  130. Green, 2006, p53 and metabolism: inside the TIGAR, Cell, 126, 30, 10.1016/j.cell.2006.06.032 · DOI · Paper page
  131. Kumar, 2018, Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers, Nat. Commun., 9, 3931, 10.1038/s41467-018-05805-1 · DOI
  132. Steck, 1997, Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers, Nat. Genet., 15, 356, 10.1038/ng0497-356 · DOI · Paper page
  133. Jiang, 2008, PI3K/PTEN signaling in tumorigenesis and angiogenesis, Biochim. Biophys. Acta, 1784, 150, 10.1016/j.bbapap.2007.09.008 · DOI · Paper page
  134. Lee, 2018, The functions and regulation of the PTEN tumour suppressor: new modes and prospects, Nat. Rev. Mol. Cell Biol., 19, 547, 10.1038/s41580-018-0015-0 · DOI · Paper page
  135. Zhang, 2010, PI(3)king apart PTEN’s role in cancer, Clin. Cancer Res., 16, 4325, 10.1158/1078-0432.CCR-09-2990 · DOI · Paper page
  136. Altinoglu, 2016, Intracellular delivery of the PTEN protein using cationic lipidoids for cancer therapy, Biomater. Sci., 4, 1773, 10.1039/C6BM00580B · DOI · Paper page
  137. Hopkins, 2013, A secreted PTEN phosphatase that enters cells to alter signaling and survival, Science, 341, 399, 10.1126/science.1234907 · DOI · Paper page
  138. Saito, 2003, Adenovirus-mediated transfer of the PTEN gene inhibits human colorectal cancer growth in vitro and in vivo, Gene Ther., 10, 1961, 10.1038/sj.gt.3302100 · DOI
  139. Tomioka, 2008, Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation, Mol. Cancer Ther., 7, 1864, 10.1158/1535-7163.MCT-07-2198 · DOI
  140. Zhang, 2010, MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC), Clin. Chim. Acta, 411, 846, 10.1016/j.cca.2010.02.074 · DOI · Paper page
  141. Vidotto, 2018, Distinct subtypes of genomic PTEN deletion size influence the landscape of aneuploidy and outcome in prostate cancer, Mol. Cytogenet., 11, 1, 10.1186/s13039-017-0348-y · DOI
  142. Jones, 2013, Comprehensive analysis of PTEN status in breast carcinomas, Int. J. Cancer, 133, 323, 10.1002/ijc.28021 · DOI
  143. Duan, 2015, PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype, Nat. Commun., 6, 10068, 10.1038/ncomms10068 · DOI · Paper page
  144. Peng, 2014, Genome-wide transcriptome profiling of homologous recombination DNA repair, Nat. Commun., 5, 3361, 10.1038/ncomms4361 · DOI · Paper page
  145. Mathur, 2017, PTEN regulates glutamine flux to pyrimidine synthesis and sensitivity to dihydroorotate dehydrogenase inhibition, Cancer Discov., 7, 380, 10.1158/2159-8290.CD-16-0612 · DOI · Paper page
  146. Garcia-Cao, 2012, Systemic elevation of PTEN induces a tumor-suppressive metabolic state, Cell, 149, 49, 10.1016/j.cell.2012.02.030 · DOI · Paper page
  147. Zhou, 2019, Effect of PTEN loss on metabolic reprogramming in prostate cancer cells, Oncol. Lett., 17, 2856
  148. Nevins, 2007, Mining gene expression profiles: expression signatures as cancer phenotypes, Nat. Rev. Genet., 8, 601, 10.1038/nrg2137 · DOI · Paper page
  149. Furge, 2007, Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling, Oncogene, 26, 1346, 10.1038/sj.onc.1210256 · DOI
  150. Bild, 2006, Oncogenic pathway signatures in human cancers as a guide to targeted therapies, Nature, 439, 353, 10.1038/nature04296 · DOI · Paper page
  151. Jeon, 2018, In silico drug combination discovery for personalized cancer therapy, BMC Syst. Biol., 12, 16, 10.1186/s12918-018-0546-1 · DOI
  152. Jerby-Arnon, 2014, Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality, Cell, 158, 1199, 10.1016/j.cell.2014.07.027 · DOI · Paper page
  153. Lee, 2018, Harnessing synthetic lethality to predict the response to cancer treatment, Nat. Commun., 9, 2546, 10.1038/s41467-018-04647-1 · DOI · Paper page
  154. Magen, 2019, Beyond synthetic lethality: charting the landscape of pairwise gene expression states associated with survival in Cancer, Cell Rep., 28, 938, 10.1016/j.celrep.2019.06.067 · DOI
  155. Preuer, 2018, DeepSynergy: predicting anti-cancer drug synergy with Deep Learning, Bioinformatics, 34, 1538, 10.1093/bioinformatics/btx806 · DOI · Paper page
  156. Sinha, 2017, Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data, Nat. Commun., 8, 15580, 10.1038/ncomms15580 · DOI

Cited by

See all 118

Metadata

Authors
Mottini, C., Napolitano, F., Li, Z., Gao, X., & Cardone, L.
Venue
Seminars in Cancer Biology
Publisher
Elsevier BV
Published
2021-01
Volume
68
Pages
59-74
ISSN
1044-579X (ISSN-L)
OpenAlex
W2975915853
Cited by
118
References
48
FWCI
7.20
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • National Cancer Institute
  • King Abdullah University of Science and Technology (FCC/1/1976-18-01, FCC/1/1976-23-01, FCC/1/1976-25-01, FCC/1/1976-26-02, FCS/1/4102-02-01)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.